Clearside Biomedical (CLSD) Revenue & Revenue Breakdown
Clearside Biomedical Revenue Highlights
Latest Revenue (Y)
$8.23M
Latest Revenue (Q)
$90.00K
Main Segment (Y)
License
Clearside Biomedical Revenue by Period
Clearside Biomedical Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $8.23M | 519.89% |
| 2022-12-31 | $1.33M | -95.51% |
| 2021-12-31 | $29.57M | 274.65% |
| 2020-12-31 | $7.89M | 263.28% |
| 2019-12-31 | $2.17M | 7143.33% |
| 2018-12-31 | $30.00K | -91.30% |
| 2017-12-31 | $345.00K | -33.65% |
| 2016-12-31 | $520.00K | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Clearside Biomedical generated $8.23M in revenue during NA 2023, up 519.89% compared to the previous quarter, and up 27420.00% compared to the same period a year ago.
Clearside Biomedical Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $90.00K | -60.87% |
| 2024-03-31 | $230.00K | -96.38% |
| 2023-12-31 | $6.34M | 638.65% |
| 2023-09-30 | $859.00K | -15.62% |
| 2023-06-30 | $1.02M | 25350.00% |
| 2023-03-31 | $4.00K | -98.79% |
| 2022-12-31 | $330.00K | 24.06% |
| 2022-09-30 | $266.00K | -30.73% |
| 2022-06-30 | $384.00K | 10.66% |
| 2022-03-31 | $347.00K | -98.65% |
| 2021-12-31 | $25.69M | 735.62% |
| 2021-09-30 | $3.07M | 294.10% |
| 2021-06-30 | $780.00K | 2194.12% |
| 2021-03-31 | $34.00K | 209.09% |
| 2020-12-31 | $11.00K | -99.68% |
| 2020-09-30 | $3.43M | 869.49% |
| 2020-06-30 | $354.00K | -91.36% |
| 2020-03-31 | $4.10M | 110.97% |
| 2019-12-31 | $1.94M | 1277.30% |
| 2019-09-30 | $141.00K | 213.33% |
| 2019-06-30 | $45.00K | - |
| 2019-03-31 | $45.00K | 50.00% |
| 2018-12-31 | $30.00K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $55.00K | -64.52% |
| 2017-09-30 | $155.00K | 19.23% |
| 2017-06-30 | $130.00K | 2500.00% |
| 2017-03-31 | $5.00K | - |
| 2016-12-31 | $5.00K | - |
| 2016-09-30 | $5.00K | - |
| 2016-06-30 | $5.00K | -99.01% |
| 2016-03-31 | $505.00K | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | - |
Clearside Biomedical generated $90.00K in revenue during Q2 2024, up -60.87% compared to the previous quarter, and up 2250.00% compared to the same period a year ago.
Clearside Biomedical Revenue Breakdown
Clearside Biomedical Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License | $8.20M | $1.30M | - | - | - |
| Other Agreement | - | - | $13.00K | $200.00K | - |
| License And Service | - | - | - | - | $105.00K |
Clearside Biomedical's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|
| License And Service | $200.00K | $141.00K | $45.00K | $45.00K |
Clearside Biomedical's latest quarterly revenue breakdown by segment (product or service), as of Jun 20: License And Service (100.00%).
Clearside Biomedical Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Jun 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|
| License And Service | $200.00K | $141.00K | $45.00K | $45.00K |
Clearside Biomedical's latest quarterly revenue breakdown by geography, as of Jun 20: License And Service (100.00%).
Clearside Biomedical Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OCUL | Ocular Therapeutix | $58.44M | $14.71M |
| CLSD | Clearside Biomedical | $8.23M | $90.00K |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| INBX | Inhibrx Biosciences | $1.80M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| EYEN | Eyenovia | $3.79K | $4.99K |
| DSGN | Design Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| INZY | Inozyme Pharma | - | - |
| NXTC | NextCure | - | - |
| GRPH | LENZ Therapeutics | - | - |
| ERAS | Erasca | - | - |
| DRTS | Alpha Tau Medical | - | - |
| EPIX | ESSA Pharma | - | - |
| SNSE | Sensei Biotherapeutics | - | - |
| MACK | Merrimack Pharmaceuticals | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| TNYA | Tenaya Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
CLSD Revenue FAQ
What is Clearside Biomedical’s yearly revenue?
Clearside Biomedical's yearly revenue for 2023 was $8.23M, representing an increase of 519.89% compared to 2022. The company's yearly revenue for 2022 was $1.33M, representing a decrease of -95.51% compared to 2021. CLSD's yearly revenue for 2021 was $29.58M, representing an increase of 274.65% compared to 2020.
What is Clearside Biomedical’s quarterly revenue?
Clearside Biomedical's quarterly revenue for Q2 2024 was $90K, a -60.87% decrease from the previous quarter (Q1 2024), and a -91.16% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $230K, a -96.38% decrease from the previous quarter (Q4 2023), and a 5650.00% increase year-over-year (Q1 2023). CLSD's quarterly revenue for Q4 2023 was $6.34M, a 638.65% increase from the previous quarter (Q3 2023), and a 1822.73% increase year-over-year (Q4 2022).
What is Clearside Biomedical’s revenue growth rate?
Clearside Biomedical's revenue growth rate for the last 3 years (2021-2023) was -72.19%, and for the last 5 years (2019-2023) was 278.55%.
What are Clearside Biomedical’s revenue streams?
Clearside Biomedical's revenue streams in c 23 are License
What is Clearside Biomedical’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Clearside Biomedical was License. This segment made a revenue of $8.2M, representing 100.00% of the company's total revenue.